Novel therapies for bile acid–mediated disorders.
VL-001, our lead asset, is a targeted bile acid sequestrant in pre-clinical development for bile acid diarrhea — a class of conditions affecting millions of patients with no FDA approved treatment.
Mission
Treatments that should already exist.
Bile acid–mediated disorders affect millions of people, yet most go undiagnosed or unaddressed. We're building a next generation therapeutic — designed for efficacy and tolerability from the ground up.
- Targeted
- Site-specific delivery in the lower GI tract, where bile acid pathology matters most.
- Tolerable
- Reformulated chemistry designed to address the side-effect profile of legacy sequestrants.
- Non-systemic
- A sequestrant by design — acting locally in the gut, not absorbed into circulation.
The Program
A new approach to bile acid sequestration.
Bile acids drive normal digestion — but when their cycle is disrupted, the result is chronic, debilitating disease. Existing sequestrants work, but their tolerability and dosing have limited adoption for decades. Our lead program rethinks the chemistry and the delivery to change that.
See the full pipelineLeadership
Decades of drug development, focused on one problem.
A team that has carried therapeutics from discovery through commercialization in GI, hepatology, and metabolic disease.
Meet the team- JP BenyaPresident & CEO
- Lisa Pedicone, PhDSVP, Medical
- Steve PetruccelliSVP, Finance & Operations
- Paul UrsinoVP, Product Development
- Catherine Coffey RossVP, Corporate Development